Recently, the U.S. Food and Drug Administration (FDA) approved the supplemental new drug application for Trelegy Ellipta for the maintenance treatment of asthma in patients ages 18 years and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback